DiaMedica Therapeutics develops DM199, an experimental protein therapy for preeclampsia, fetal growth restriction and acute ischemic stroke. DMAC reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 11 | HC Wainwright & Co. | Reiterated | Buy |
Seasonality
How DMAC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.
Whale Options Flow
90DNo whale options trades in DMAC in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DMAC is in one of them and how their past DMAC trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered DMAC in an article yet. Here's the latest on the wider market.
About DiaMedica Therapeutics
DiaMedica Therapeutics is a biopharmaceutical company based in Minneapolis, Minnesota. It is developing DM199, a recombinant form of the human tissue kallikrein-1 protein, as a possible treatment for preeclampsia, fetal growth restriction and acute ischemic stroke. The drug is still in clinical trials and is not yet approved for sale. The company is also working on DM300, a recombinant ulinastatin, as a possible treatment for severe acute pancreatitis.
- Headquarters
- Minneapolis, MN